STREAM is a collaboration of researchers who share a common set of principles about the goals and methods for studying clinical translation. We apply empirical and philosophical tools for addressing scientific, ethical, and policy challenges in the development and translation of health technologies. Our members work in ethics, epidemiology, biology, psychology, and various medical specialties. The network is centered at McGill University, and has affiliates throughout North America and abroad.
STREAM is inviting applications for postdoctoral research fellows (PDF). Please see job postings for details on these two positions:
One PDF position requires a background in judgment and decision-making. The project will examine how researchers make judgments about risk, benefit, and priorities in drug development- and whether there are ways to improve the effectiveness of their decision-making.
The second PDF position requires a background a background in clinical trials or ethics. The project will examine how risk, benefit, burdens, and clinical hypotheses evolve as new drugs are developed- and whether there are ways to improve efficiencies in clinical development. The project will also apply forecast methods.
Dr. Kimmelman was also interviewed for CBC's Second Opinion.
Jonathan Kimmelman quoted in MIT Technology Review
Jonathan Kimmelman gives his take on underreporting of adverse events in trial reports: Des effets secondaires des médicaments restent absents des publications scientifiques in Le Devoir
Jonathan Kimmelman quoted in the Portland Press Herald
Jonathan Kimmelman quoted in CMAJ
Jonathan Kimmelman's work for the new International Society for Stem Cell Research guidelines featured in Nature!
Work of STREAM profiled in Nature Reviews Clinical Oncology
Mattina J, Carlisle B, Hachem Y, Fergusson D, Kimmelman J. Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review. PLOS Biology February 3, 2017.
Kimmelman J. and Federico C. Consider drug efficacy before first-in-human trials. Nature January 30, 2017.
Kimmelman J. Is Participation in Cancer Phase I Trials Really Therapeutic? Journal of Clinical Oncology. 2016.
Barsanti-Innes B, Hey SP, Kimmelman J. The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing The Oncologist. 2016.